Mechanisms involved in metformin action in the treatment of polycystic ovary syndrome

Current Pharmaceutical Design

Volumn 15, Issue 26, 2009, Pages 3074-3077

  Motta, A B ^a  

^a Centre de Estudios Farmacologicos y Botanicos   (Argentina)

Author keywords

Adolescents; Cardiovascular; Diabetes; Metformin; Ovulation; Polycystic ovary syndrome (PCOS); Pregnancy

Indexed keywords

ADENYLATE KINASE; C REACTIVE PROTEIN; METFORMIN; N(G),N(G) DIMETHYLARGININE;

ANTIHYPERGLYCEMIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ENERGY; CELL FUNCTION; DRUG ACTIVITY; ENDOTHELIUM; ENZYME ACTIVITY; HUMAN; LIPID PEROXIDATION; OBESITY; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; OXIDATIVE STRESS; PRIORITY JOURNAL; REPRODUCTION; REVIEW;

ANIMALS; FEMALE; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; PREGNANCY;

EID: 70449458835     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209789058101     Document Type: Review

References (63)

1. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333(13): 853-861
2. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metabol 2000; 85(7): 2434-2438 (Pubitemid 32269197)
3. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome- a hypothesis. J Endocrinol 2002; 174(1): 1-5. (Pubitemid 34830927)
4. Moghetti PR, Castello R, Negri C, Tosi F, Perrone F, Caputo M, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo- controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metabol 2000; 85(1): 139-146 (Pubitemid 32268804)
5. Glueck CJ, Fontaine RN, Wang P, Subbiah MT, Weber K, Illig E, et al. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism 2001; 50(7) : 856-861
6. Jakubowicz DJ, Sépala M, Jakubowicz S, Rodríguez-Armas O, Rivas- Santiago A, Koistinen K, et al. Insulin Reduction with Metformin increases luteal phase serum Glycodelin and Insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in he polycystic ovary syndrome. J Clin Endocrinol Metabol 2001; 86(3): 1126-1133 (Pubitemid 32322992)
7. Faure P, Rossini E, Wiernsperger N. An insulin sensitizer improves the free radical defense system potential and insulin sensitivity in high fructose-fed rats. Diabetes 1999; 48(2): 353-357 (Pubitemid 29061110)
8. Ceriello, A. Oxidative stress and glycemic regulation. Metabolism 2000; 49(2): 27-29
9. Srividhya S, Ravichandran MK, Anuradha CV. Metformin attenuates blood lipid peroxidation and potentiates antioxidant defense in high fructose-fed rats. J Biochem Mol Biol Biophys 2000; 6(6): 379-385 (Pubitemid 35469235)
10. Bonnefont-Rousselot D, Raji B, Walrand M, Gardes-Albert M, Jore D, Legrand A, et al. An intracellular modulation of free radical production could contribute to the beneficial effects of metformin towards oxidative stress. Metabolism 2003; 52(5): 586-589 (Pubitemid 36896285)
11. Elia E, Sander V, Luchetti CG, Solano ME, Di Girolamo G, Gonzalez C, et al. The mechanisms involved in the action of metformin in regulating ovarian function in hyperandrogenized mice. Mol Hum Reprod 2006; 12(8): 475-481 (Pubitemid 44288192)
12. Sander V, Luchetti CG, Elia E, Solano ME, Di Girolamo G, Gonzalez C, et al. Role of the N,N′- dimethylbiguanide metformin in the treatment of female prepuberal BALB/c mice hyperandrogenized with dehydroepiandrosterone. Reproduction 2006; 131(3): 591-602.
13. Solano ME, Sander V, Elia E, Luchetti CG, Di Girolamo G, Gonzalez C, et al. Metformin prevents embryonic resorption induced by hyperandrogenization with dehydroepiandrosterone in mice. Reprod Fertil Dev 2006; 18(5): 533-544 (Pubitemid 43806922)
14. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP- activated protein kinase in mechanism of metformin action. J Clin Investigat 2001; 108(8): 1167-1174 (Pubitemid 32995375)
15. Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002; 51(7): 2074-2081 (Pubitemid 34729010)
16. Zou MH, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles WG, Schlattner U, et al. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. J Biolog Chem 2004; 279(42): 43940-43951
17. Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D, et al. LKB1 is the upstream kinase in the AM-Pactivated protein kinase cascade. Curr Biol 2003; 13(22): 2004-2008 (Pubitemid 37425212)
18. El-Mir MY, Nogueira V, Fontaine E, Haberte N, Rigoulet M, Levere X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biolog Chem 2000; 275(1): 223-228 (Pubitemid 30038975)
19. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000; 15(3): 607-614 (Pubitemid 30410251)
20. Hawley SA, Gadalla AE, Olsen GS, Hardie DG. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide- independent mechanism. Diabetes 2002; 51 (8): 2420-2425
21. Fryer LG, Parbu-Patel A, Carling D. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biolog Chem 2002; 277(28): 25226-25232 (Pubitemid 34951829)
22. Frederich M, Balschi JA. The relationship between AMP-activated protein kinase activity and AMP concentration in the isolated perfused rat heart. J Biolog Chem 2002; 27(3): 1928-1932 (Pubitemid 34968770)
23. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002; 415(6869): 339-343 (Pubitemid 34087557)
24. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, et al. Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J Clin Endocrinolog Metabol 2007; 93(3): 792-1300
25. Heutling D, Schulz H, Nickel I, Kleinstein J, Kaltwasser P, Westphal S, et al. Asymmetric dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J Clin Endocrinol Metabol 2008; 93(6): 82-90.
26. Mitchell RA, Liao H, Chesney J, Fingerle-Rowson G, Baugh J, David J, et al. Macrophage migration inhibitory factor (MIF) sustains macrophage macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci USA 2002; 99(1): 345-350 (Pubitemid 34060365)
27. Roger T, Glauser MP, Calandra T. Macrophage migration inhibitory factor (MIF) modulates innate immune responses induced by endotoxin and Gram-negative bacteria. J Endotoxin Research 2001; 7(6): 456-460 (Pubitemid 34048531)
28. Froidevaux C, Roger T, Martin C, Glauser MP, Calandra T. Macrophage migration inhibitory factor and innate immune responses to bacterial infections. Crit Care Med 2001; 29(7): S13-5 (Pubitemid 32681575)
29. Dandona P, Aljada A, Ghanim H, Mohanty P, Tripathy C, Hofmeyer D, et al. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin . J Clin Endocrinol Metabol 2004; 89(10): 5043-5047 (Pubitemid 39391446)
30. Gonzalez F, Thusu K, Abdel-Rahman E, Prabhala A, Tomani M, Dandona P. Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome. Metabolism 1999; 48(4): 437-441 (Pubitemid 29174220)
31. Gonzalez F, Rote NS, Minium J, Kirwan JP. Increased activation of nuclear factor kappaB triggers inflammation and insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91(4): 1508-1512
32. Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arterioscler Thromb Vasc Biol 2006; 26(3): 611-617
33. Yang TL, Chen MF, Luo BL, Xie QY, Jiang JL, Li YJ. Fenofibrate decreases asymmetric dimethylarginine level in cultured endothelial cells by inhibiting NF-kappaB activity. Naunyn Schmiedebergs Arch Pharmacol 2005; 371(5): 401-407
34. Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metabol 2000; 85(8): 2970-2973 (Pubitemid 32269184)
35. Aljada A, Friedman J, Ghanim H, Mohanty P, Hofmeyer D, Chaudhuri A, et al. Glucose ingestion induces an increase in intranuclear nuclear factor kappaB, a fall in cellular inhibitor kappaB, and an increase in tumor necrosis factor alpha messenger RNA by mononuclear cells in healthy human subjects. Metabolism 2006; 55(9): 1177-1185
36. Chu NV, Kong APS, Kim DP, Armstrong D, Baxi S, Deutch R, et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 2002; 25(3): 542-549 (Pubitemid 41103350)
37. Rosen P, Nawroth PP, King G, Moller W, Tritchler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a congress series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001; 17(3): 189-212. (Pubitemid 32624602)
38. Youssef S, Nguyen DT, Soulis T et al. Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding. Kidney Int 1999; 55(3): 907-916 (Pubitemid 29100702)
39. Srividhya S, Ravichandran MK, Anuradha CV. Metformin attenuates blood lipid peroxidation and potentiates antioxidant defense in high fructose-fed rats. J Biochem Mol Biol Biophys 2002; 6(6): 379-385 (Pubitemid 35469235)
40. Trivin F, Chevenne D, Hautecouverture M. Maillard reaction products and chronic diabetic complications. Annal Biol Clin 1999; 57(4): 445-454
41. Tessier D, Maheux P, Khalil A, Fulop T. Effect of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes. Metabolism 1999; 48(7): 897-903. (Pubitemid 29310047)
42. Pavlovic D, Kocic R, Kocic G, Jevlovic T, Radenkovic S, Mikle D, et al. Effect of four week metformin treatment on plasma and erythrocyte anti oxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes. Diabetes Obes Metab 2000; 2(4): 251-256 (Pubitemid 33072194)
43. Khouri H, Collin F, Bonnefont-Rousselot D, Legrand A, Jore D, Gardès-Albert M. Radical-induced oxidation of metformin. Eur J Biochem 2004; 271(23-24): 4745-4752
44. Ewis SA, Abdel-Rahman MS. Effect of metformin on glutathione and magnesium in normal and streptozotocin-induced diabetic rats. J Appl Toxicol 1995; 15(5): 387-390
45. Tanaka Y, Uchino H, Shimizu T, Yoshii H, Njwa M, Ohmura C, et al. Effect of metformin on advanced glycation end product formation and peripheral nerve function in streptozocin-induced diabetic rats. Eur J Pharmacol 1999; 376(1-2): 17-22. (Pubitemid 29320165)
46. Ruggiero-Lopez D, Lecomte M, Moinet G, Patereau G, Lagarde M, Wiernsperger N. Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem Pharmacol 1999; 58(11):1765-1773
47. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metabol 2004; 89(6): 2728-2735 (Pubitemid 38766357)
48. Froment P, Touraine P. Thiazolidinediones and Fertility in Polycystic Ovary Syndrome (PCOS). PPAR Res 2006; 2006: 73986.
49. Dahlgren E, Jansen PO, Johansson S, Lapidus L, Odén A. Polycystic ovary syndrome and risk for myocardial infraction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gyencolog Scand 1992; 71(8): 599-604.
50. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at log term follow-up. J Clin Epidemiol 1998; 51(7): 581-586 (Pubitemid 28376967)
51. Ferri C, Desideri G, Baldoncini R, Bellini C, De Angelis C, Mazzocchi C, et al. Early activation of vascular endothelium in nonobese, nondiabetic essential hypertensive patients with multiple metabolic abnormalities. Diabetes 1998; 47(4): 660-667 (Pubitemid 28160459)
52. Reaven GM, Chen YD. Insulin resistance, its consequences and coronary heart disease mus we choose on culprit?. Circulation 1996; 93(10): 1780-1783
53. Prevelic GM, Beljic T, Balint-Peric L, Ginsburg J. Cardiac flow velocity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1995; 43(3): 677-681 (Pubitemid 26015012)
54. Birdsall MA, Farquhar CM, White HD. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Annals Internal Med 1997; 126(1): 32-35
55. McCredie RJ, McCrohon JA, Turner L, Griffiths KA, Handelsman DJ, Celermajer DS. Vascular reactivity is impaired in genetic females taking high-dose androgens. J Am Colleague Cardiol 1998; 32(5):1331-1335 (Pubitemid 28522391)
56. Diamanti-Kandarakis E, Alexandraki K, Protogerou A, Piperi C, Papamichael C, Aessopos A, et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol 2005; 152(5): 749-756 (Pubitemid 40744544)
57. Palomba S, Russo T, Orio F Jr, Falbo A, Manguso F, Cascella T, et al. Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome. Hum Reprod 2006; 21(2):457-465 (Pubitemid 43159923)
58. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009; 8(6): 909-915
59. Elia EM, Belgorosky D, Faut M, Vighi S, Pustovrh C, Luigi D, et al. The effects of metformin on uterine tissue of hyperandrogenized BALB/c mice. Mol Hum Reprod 2009; In press
60. Solano ME, Sander V, Wald MR, Motta AB. Dehydroepiandrosterone and metformin regulate proliferation of murine T lymphocytes. Clin Exp Immunol 2008; 53(2): 289-296 (Pubitemid 351989166)
61. Karastergiou K, Kaski JC. Medical management of the diabetic patient with coronary artery disease. Curr Pharm Des 2008; 14(25): 2527-2536
62. Mongiovi M, Pipitone S. Supraventricular tachycardia in fetus: how can we treat ? Curr Pharm Des 2008; 14(8): 736-742
63. Motta DA. Metformin in the treatment of polycystic ovary syndrome. Curr Pharm Des 2008; 14(21): 2121-2125